Related references
Note: Only part of the references are listed.Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
Stefan Froehling et al.
BLOOD (2006)
Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents
A. J. Barrett et al.
LEUKEMIA (2006)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome
M de Lima et al.
SEMINARS IN HEMATOLOGY (2006)
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
A Shimoni et al.
LEUKEMIA (2006)
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
U Hegenbart et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia
S Tauro et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)
M Aoudjhane et al.
LEUKEMIA (2005)
Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'
AA Kassim et al.
BONE MARROW TRANSPLANTATION (2005)
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome
K van Besien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (≥ 60 years) with active myeloid malignancies
A Spyridonidis et al.
BLOOD (2005)
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning
AYL Ho et al.
BLOOD (2004)
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
M de Lima et al.
BLOOD (2004)
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
R Wong et al.
BLOOD (2003)
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies
MB Maris et al.
BLOOD (2003)
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia
H Bertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
HJ Deeg et al.
BLOOD (2002)
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
R Chakraverty et al.
BLOOD (2002)
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
PA McSweeney et al.
BLOOD (2001)
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
S Giralt et al.
BLOOD (2001)
Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation
R Wäsch et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
